|
|
| MRD / Regn No. |
: THBC\23-24\05153 |
Date |
: 10/07/2026 |
| Patient Name |
: Mamta Samel |
Age & Gender |
: 49 Yrs. / Female |
| Contact No. |
: 9819301353 |
UHID |
: |
| Ht / Wt / BMI |
: |
BP S / BP D |
: |
| Allergies |
: NONE |
Referred By |
: |
| |
|
| Problem
List |
: |
T2DM (05/Sep/2022) | HYPOTHYROIDISM (05/Sep/2017) | DYSLIPIDEMIA (05/Jun/2024) | |
|
Subjective |
: |
T2DM SINCE 2022,HYPOTHYROIDISM SINCE 2017,DYSLIPIDEMIA SINCE JUNE 24,ERRATIC CYCLE / 2 DAYS HEAVY BLEEDING - CONSULTED GYNAEC,UMBLICAL DISCHARGE - NOW STOPPED / NO REDNESS / NO PAIN / NO FEVER - CBC NORMAL,DISCOLORATION AROUND NAIL - MOISTURISER |
|
Objective |
: |
27TH JUNE 26,HB-10.6,URINE PUS CELLS-6 TO 8,AST-27.4/ALT-22.3,CR-0.75,URIC ACID-7.5,CA-8.2,EGFR-98.14,TC-198.1/TG-142.9/LDL-135/HDL-34.9,T3-104.93/T4-9.43/TSH-2.243,VIT B12-100/VIT D3-33.41,IRON-32.81/TIBC-320.83/TRANSFERRIN SATURATION-10.23,HBA1C-7.4,FBS-112.7 |
|
|
S# |
Generic (Trade) Name |
Route |
Dosage |
Usage |
Duration |
|
1 |
THYROX 75 MCG |
ORAL |
1-0-0 |
30 MINS BBF
|
6 MTHS |
|
|
2 |
PLEOFEROL 60K |
ORAL |
ONCE EVERY 15 DAYS |
ANYTIME OF DAY
|
6 MTHS |
|
|
3 |
TABLET GLIMEPIRIDE (1MG), METFORMIN (500MG) AND VOGLIBOSE (0.2) GLYCOMET TRIO 1 |
ORAL |
1/2-0-1/2 |
BBF / BD
|
6 MTHS |
|
|
4 |
SHELCAL XT |
ORAL |
0-1-0 |
AL / 3 DAYS A WEEK
|
6 MTHS |
|
|
5 |
TABLET VILDAGLIPTIN (50MG) AND METFORMIN (500MG) ZOMELIS MET 50/500 MG |
ORAL |
1-0-1 |
BBF / BD
|
6 MTHS |
|
|
6 |
FUNGICROS NAIL LACQUER |
TOPICAL |
DAILY |
|
2 MTHS |
|
|
7 |
OINTMENT MUPIROCINE GEL 2% W/V T BACT |
TOPICAL |
DAILY |
DAILY
|
10 DAYS |
|
|
8 |
ESTRABET CREAM |
LOCAL VAGINAL APPLICATION |
LOCAL APPLICATION |
DAILY NIGHT
|
TO CONTINUE |
|
|
| |
|
|
|
| Refill :
0 / Substitution: |
|
|
| Education |
: F LOW SUGARS (<70 MG/DL),TAKE 1 TBSP(15GMS) GLUCOSE POWDER. CHECK AGAIN AFTER 15 MINS IF >100 CAN GIVE A PROTEIN MEAL. |
| Next Visit |
: 08/Apr/2026 |
| Tests Suggested For Next Visit |
: HBA1C > 3 MTHS - TEXT ME - IF CLOSE TO 6.5% - THEN SAME MEDS,AFTER 6 MTHS - HBA1C / FBS / PPBS / URINE FOR MICROALB:CREAT RATIO |
| |
|
| |
|
|